Reported 4 months ago
BillionToOne presented results at the American Society of Clinical Oncology Annual Meeting (ASCO24) showing their NorthStar Select liquid biopsy test for tumour profiling outperformed commercially available assays by detecting 43% more pathogenic variants in low variant allele fraction ranges. The assay offers a prioritised list of mutations from patients' tumours using next-generation sequencing, proving valuable as tumour profiling becomes crucial in oncology for precision therapies. The company's approach aims to address limitations present in some cancer patients with low circulating tumour DNA signals, which are common in late-stage cases.
Source: YAHOO